logo

For the Inventor, By the Inventor

Lebanon, NH, United States of America

Eric Krauland

This inventor holds 20 USPTO granted patents and 10 published patent applications and 4 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Adimab, LLC, Merrimack Pharmaceuticals, Inc., Genentech, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric Krauland. Retrieved from https://idiyas.com/inventor/eric-krauland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 60.0

 

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 35(Granted Patents)


Location History:

  • Cambridge, MA (US) (2013)
  • Lebanon, NH (US) (2013 - 2023)

Company Filing History:

goldMedal7 out of 52 
 
Adimab, LLC
 patents
silverMedal6 out of 54 
 
Merrimack Pharmaceuticals, Inc.
 patents
bronzeMedal3 out of 3,302 
 
Genentech, Inc.
 patents
4. 3 out of 36 
 
Mersana Therapeutics, Inc.
 patents
5. 2 out of 8,600 
 
Massachusetts Institute of Technology
 patents
6. 2 out of 5,644 
 
The University of Texas System
 patents
where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Monoclonal Antibodies
Dual Specificity Antibodies
BACE1
HER2 Epitope
PD-L1
PD-L2
EGFR
Anti-CD3
Transferrin Receptor
Immunotherapy
Polyclonal Mixtures
Cell Display Libraries
20 patents (USPTO):Explore Patents
1. 12258679 - Polyclonal mixtures of antibodies, and methods of making and using them (2025-03-25),
2. 12187799 - Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor (2025-01-07),
3. 12134648 - Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor (2024-11-05),
4. 11746160 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2023-09-05),
5. 11542330 - Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use (2023-01-03),
6. 11518812 - Monoclonal antibodies against HER2 epitope and methods of use thereof (2022-12-06),
7. 11390964 - Polyclonal mixtures of antibodies, and methods of making and using them (2022-07-19),
8. 11008403 - Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use (2021-05-18),
9. 10882920 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2021-01-05),
10. 10684289 - Polyclonal mixtures of antibodies, and methods of making and using them (2020-06-16),
11. 10072299 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-09-11),
12. 9902999 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-02-27),
13. 9885087 - Antibodies against epidermal growth factor receptor (EGFR) and uses thereof (2018-02-06),
14. 9738720 - Monoclonal antibodies against HER2 epitope and methods of use thereof (2017-08-22),
15. 9555112 - Monoclonal antibodies against HER2 epitope and methods of use thereof (2017-01-31),

Title: The Innovative Contributions of Eric Krauland in Antibody Development

Introduction

Eric Krauland, based in Lebanon, NH, has established himself as a significant figure in the field of biotechnology through his innovative work and numerous patents. With a total of 20 patents to his name, Krauland has made notable contributions to the advancements in antibody therapies.

Latest Patents

Among his latest patents is a groundbreaking method for creating polyclonal mixtures of antibodies. This method involves broadening the epitopic coverage of an antigen of interest by contacting a first sample of the antigen with a plurality of host cells expressing a library of antibodies. The process allows for the collection of host cells expressing antibodies that bind to the antigen, ultimately resulting in a polyclonal mixture. Additionally, Krauland has developed dual specificity antibodies that target PD-L1 and PD-L2, offering new therapeutic avenues for treating cancers associated with these proteins.

Career Highlights

Throughout his career, Eric Krauland has worked with prominent companies in the biotechnology sector, including Adimab, LLC and Merrimack Pharmaceuticals, Inc. His work in these organizations has been pivotal in advancing research and development related to antibody therapies.

Collaborations

Eric has collaborated with industry experts such as Michael Feldhaus and Neeraj Kohli. These collaborations have fostered an environment of innovation and creativity, furthering the potential of antibody-based treatments.

Conclusion

Eric Krauland stands out as a dedicated inventor whose work has the potential to significantly impact the field of antibody therapy. His inventions not only showcase his deep expertise but also reflect the collaborative spirit that drives innovation in biotechnology. As he continues to build upon his impressive portfolio of patents, Krauland remains a prominent figure in the pursuit of new medical advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…